Author

D. Shum

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Biochemistry· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 5 Approach:experimental assay· 4 Organism:human· 2 Approach:benchmark study· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Ianevski· 2 shared D. Kainov· 2 shared I. Choi· 2 shared M. Ko· 2 shared M. P. Windisch· 2 shared S. Y. Byun· 2 shared A. Bergqvist· 1 shared A. d. M. Czeczot· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Ianevski

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Identification and characterization of new structural scaffolds modulating the activity of Mycobacterium tuberculosis dihydroneopterin aldolase (FolB) in vitro

V. C. d. A. Falcao, A. d. M. Czeczot, M. M. Alam, K.-H. P. Park, J. Heo, M. Woo, A. M. Camini, L. F. S. M. Timmers, D. Shum, M. A. Perello, L. A. Basso, P. Machado, C. V. Bizarro, V. P. Delorme

The paper identifies and characterizes new structural scaffolds that modulate the activity of Mycobacterium tuberculosis dihydroneopterin aldolase (FolB) in vitro, finding compounds with IC50 values ranging from 2.6 to 47 μM.

bioRxiv · Nov 21, 2023 · PreprintBiochemistry

Antiproliferative Activity of Cephalotaxus Esters: Overcoming Chemoresistance in Cancer Therapy

V. Yong-Gonzalez, C. Radu, P. A. Calder, D. Shum, M. G. Frattini, H. Djaballah

This study evaluates the antiproliferative effects of HHT and its derivatives against cancer cells, finding that they overcome MDR1-mediated resistance in some cell lines but are effective against primary leukemia cells.

bioRxiv · Nov 6, 2023 · PreprintPharmacology & Toxicology

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

S. Jeon, M. Ko, J. Lee, I. Choi, S. Y. Byun, S. Park, D. Shum, S. Kim

This study screens 48 FDA-approved drugs for antiviral efficacy against SARS-CoV-2 and identifies 24 drugs with IC50 values between 0.1 M and 10 M, including niclosamide and ciclesonide.

bioRxiv · Mar 20, 2020Microbiology

Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19

M. Ko, S. Y. Chang, S. Y. Byun, A. Ianevski, I. Choi, A. L. P. H. d'Alexandry d'Orengiani, D. Kainov, D. Shum, J.-Y. Min, M. P. Windisch

The paper screens FDA-approved drugs against a MERS-CoV isolate to identify potential therapies for COVID-19, finding several drugs with therapeutic indexes >6 and synergistic combinations.

bioRxiv · Feb 25, 2020Microbiology

Critical Nodes of Virus-Host Interaction Revealed Through an Integrated Network Analysis

K. Bosl, A. Ianevski, T. T. Than, P. I. Andersen, S. Kuivanen, M. Teppor, E. Zusinaite, U. Dumpis, A. Vitkauskiene, R. J. Cox, H. Kallio-Kokko, A. Bergqvist, T. Tenson, V. Oksenych, M. Bjoras, , R. K. Kandasamy

This study identifies critical host-virus interaction nodes through network analysis and drug re-purposing, revealing key targets for antiviral therapies.

bioRxiv · Feb 13, 2019 · PreprintImmunology